In 1995 the International Agency for Research on Cancer (IARC) completed a study that involved nuclear workers from facilities in the USA, UK and Canada. The only significant, though weak, dose-related associations found were for leukaemia and multiple myeloma. The results for the Canadian cohort, which comprised workers from the facilities of Atomic Energy of Canada Limited (AECL), were compatible with those for the other national cohorts. In 2005, IARC completed a further study, involving nuclear workers from 15 countries, including Canada. In these results, the dose-related risk for leukaemia was not significant but the prominent finding was a statistically significant excess relative risk per sievert (ERR Sv(-1)) for 'all cancers excluding leukaemia'. Surprisingly, the risk ascribed to the Canadian cohort for all cancers excluding leukaemia, driven by the AECL sub-cohort, was significantly higher than the risk estimate for the 15-country cohort as a whole. We have attempted to identify why the results for the AECL cohort were so discrepant and had such a remarkable influence on the 15-country risk estimate. When considering the issues associated with data on the AECL cohorts and their handling, we noted a striking feature: a major change in outcome of studies that involved Canadian nuclear workers occurred concomitantly with the shift to when data from the National Dose Registry (NDR) of Canada were used directly rather than data from records at AECL. We concluded that an important contributor to the considerable upward shift in apparent risk in the 15-country and other Canadian studies that have been based on the NDR probably relates to pre-1971 data and, in particular, the absence from the NDR of the person-years of workers who had zero doses in the calendar years 1956 to 1970. Our recommendation was for there to be a comprehensive evaluation of the risks from radiation in nuclear industry workers in Canada, organisation by organisation, in which some of the anomalies that we have identified might be addressed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1088/0952-4746/30/2/001 | DOI Listing |
CNS Drugs
January 2025
Innovative Medicines and Global Clinical Development, Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.
Background: Huntington disease (HD) is a progressive neurodegenerative disease that causes psychiatric and neurological symptoms, including involuntary and irregular muscle movements (chorea). Chorea can disrupt activities of daily living, pose safety issues, and may lead to social withdrawal. The vesicular monoamine transporter 2 inhibitors tetrabenazine, deutetrabenazine, and valbenazine are approved treatments that can reduce chorea.
View Article and Find Full Text PDFLancet Diabetes Endocrinol
January 2025
Centre for Endocrinology and Metabolism, Hudson Institute of Medical Research, Clayton, VIC, Australia; Department of Endocrinology, Monash Health, Clayton, VIC, Australia.
Background: Primary aldosteronism can be treated medically but there is no standardised method to evaluate treatment outcomes. We aimed to develop criteria for assessing the outcomes of targeted medical treatment of primary aldosteronism, analyse outcomes across an international cohort, and identify factors associated with a complete treatment response.
Methods: An international panel of 31 primary aldosteronism experts used the Delphi method to reach consensus on the definition of complete, partial, or absent biochemical and clinical outcomes of medical treatment of primary aldosteronism.
PLoS One
January 2025
Department of Electrical and Computer Engineering, University of Toronto, Toronto, Ontario, Canada.
There is a growing need to document sociodemographic factors in electronic medical records to produce representative cohorts for medical research and to perform focused research for potentially vulnerable populations. The objective of this work was to assess the content of family physicians' electronic medical records and characterize the quality of the documentation of sociodemographic characteristics. Descriptive statistics were reported for each sociodemographic characteristic.
View Article and Find Full Text PDFInt J Cancer
January 2025
Division of Cancer Epidemiology, Department of Oncology, McGill University, Montréal, Québec, Canada.
There is a paucity of disaggregated data to monitor cancer health inequalities in Canada. We used data linkage to estimate site-specific cancer relative survival by race, immigration status, household income, and education level in Canada. We pooled the Canadian Census Health and Environment Cohorts, which are linked datasets of 5.
View Article and Find Full Text PDFBackground: LIGHT (oLaparib In HRD-Grouped Tumor types; NCT02983799) prospectively evaluated olaparib treatment in patients with platinum-sensitive relapsed ovarian cancer (PSROC) assigned to cohorts by known BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: germline BRCAm (gBRCAm), somatic BRCAm (sBRCAm), HRD-positive non-BRCAm, and HRD-negative. At the primary analysis, olaparib treatment demonstrated activity across all cohorts, with greatest efficacy in terms of objective response rate and progression-free survival observed in the g/sBRCAm cohorts. The authors report final overall survival (OS).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!